Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1An open‐label, unit dose‐finding study of AMG 531, a novel thrombopoiesis‐stimulating peptibody, in patients with immune thrombocytopenic purpura2006 · 150 citations
2. 2Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program2011 · 113 citations
3. 3International consensus report on the investigation and management of primary immune thrombocytopenia2009 · 2,281 citations
4. 4Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance.1987 · 403 citations
5. 5Thrombopoietin and Thrombopoietin Mimetics in the Treatment of Thrombocytopenia2008 · 182 citations